Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: Abbvie - The Real Truth

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

These three Dividend Aristocrats offer yields above 3% and a history of consistent dividend growth, making them strong choices to help stay ahead of inflation.

MarketBeat

3 Companies Aggressively Raising Dividends While Others Play Defense

A strong dividend stock may not only pay a healthy distribution, but also be able to continue to grow its payouts thanks to steady, strong business.

MarketBeat

What You Need to Know Ahead of AbbVie’s Earnings Release

AbbVie will release its first-quarter earnings this month, and analysts anticipate a double-digit bottom-line growth.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

Three companies with a combination of excellent name recognition within their industries and strong free cash flow potential provide a stable investment option.

MarketBeat

AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal

AbbVie is on track to grow, drive cash flow, and pay a healthy dividend for the long term: institutions and analysts are accumulating this stock.

MarketBeat

AbbVie Stock: Analyst Estimates & Ratings

After Humira’s patent cliff, what do analysts think about AbbVie’s stock now?

Barchart

The 3 Most Reliable Dividend Stocks to Buy for Years to Come

These three dividend stocks are long-term winners with dependable payouts.

Barchart

Read news from The Economist, FT, and more,
with one subscription

AbbVie Call Options Spike 2,599%: Tracking the Big Bet

Large institutional investors are positioning for growth as a leading biopharmaceutical firm enters the obesity market and reaches a federal agreement.

MarketBeat

Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

MarketBeat

What to Expect From AbbVie's Next Quarterly Earnings Report

AbbVie will release its fourth-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.

Barchart

2 Dividend Kings Quietly Beating the Market This Year

These two are the calm outperformers that might have been overlooked.

Barchart

3 Dividend Growth Stocks Analysts Are Upgrading for 2026

United Parcel Service, PepsiCo, and AbbVie are healthy dividend payers whose analyst trends support an outlook for price strength in 2026.

MarketBeat

3 Dividend Kings Delivering Generational Income & Market-Beating Returns

3 top-performing Dividend Kings of 2025 based on their Year-to-Date percent change.

Barchart

AbbVie’s (ABBV) Options Flow Implies That the Smart Money Could Be Up to Something

An intriguing quant signal combined with shifting sentiment in the derivatives market opens the possibility toward a bullish trade for ABBV stock.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul

AbbVie, McDonald’s, and Walmart offer growth, rising dividends, and valuation upside as investors seek blue-chip stability heading into 2026

Barchart

3 Dividend Aristocrats on the Edge of a Big Move

Discover three high-yield Dividend Aristocrats showing strong fundamentals and analyst support as they set up for a potential breakout.

Barchart

3 Highest-Yielding Dividend Kings To Buy, Hold, and Forget

Discover three Dividend Kings built for buy-and-forget wealth. These stable giants may quietly deliver income and growth for decades.

Barchart

Is AbbVie Stock Outperforming the Nasdaq?

AbbVie has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

How This 'Hidden Gold Mine' Has Beaten The Market For 30 Years

For three decades, I have watched investors chase the latest hot stock, the newest tech darling, and the most hyped IPO. Meanwhile, a sleepy corner of the market has been quietly minting fortunes.

MarketBeat

Healthcare Rotation Underway: 3 Stocks Leading the Charge

Are healthcare stocks finally back in fashion? After years of underperformance, a healthcare rotation is underway, led by these three innovative drug makers.

Barchart

3 High-Growth Dividend Kings For Generations of Income - And Still Rated “Buy”

Dividend Kings with 20%+ YTD gains and strong analyst ratings show rare momentum, reliable income, and long-term stability across multiple sectors.

Barchart

3 Dividend Aristocrats Every Diversified Portfolio Should Include

Win through diversification: mix stable, income-generating Dividend Aristocrats for growth, reliability, and long-term returns.

Barchart

AbbVie Just Raised Its Dividend by 5.5%. Should You Buy ABBV Stock Here?

AbbVie just increased its dividend by 5.5%, raising the quarterly payout to $1.73 per share starting February 2026, reflecting strong confidence in its long-term growth driven by new drugs like Skyrizi and Rinvoq.

Barchart

1 High-Risk, High-Reward Way to Trade Earnings with 0DTE Options

Traders are increasingly turning to zero-days-to-expiration (0DTE) options to target fast-moving market reactions, including earnings announcements. The high leverage and compressed timeframe offered by these setups can deliver outsized returns, but those same dynamics leave little margin for error when it comes to timing and execution.

Barchart

Do Wall Street Analysts Like AbbVie Stock?

Although AbbVie has underperformed the S&P 500 Index over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

1 2 3 4 5

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

363,113 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.